Pirtobrutinib for the Treatment of B-Cell Malignancies: Recent Developments
Bruton tyrosine kinase (BTK) plays a vital role in B-cell functions, including differentiation, proliferation and survival, and has emerged as a critical therapeutic target of several generations of kinase inhibitors. Approved covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib...
| Published in: | healthbook TIMES. Oncology Hematology |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-12-01
|
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.22.162 |